Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

International Journal of Obesity

Volumn 38, Issue 5, 2014, Pages 689-697

  Lean, M E J ^a   Carraro, R ^b   Finer, N ^c   Hartvig, H ^d   Lindegaard, M L ^d   Rossner S ^e   Van Gaal, L ^f   Astrup, A ^g  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GLP 1 analog; liraglutide; nausea; quality of life; vomiting; weight loss

Indexed keywords

LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EXERCISE; FEMALE; HUMAN; INCIDENCE; INSULIN INJECTION PEN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OBESITY; OPEN STUDY; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETCHING; SELF REPORT; TREATMENT OUTCOME; VISUAL IMPAIRMENT; WEIGHT REDUCTION; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; EUROPE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; SEVERITY OF ILLNESS INDEX; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; NAUSEA; OBESITY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING; WEIGHT LOSS;

EID: 84899906592     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2013.149     Document Type: Article

References (46)

1. Mayer MA, Hocht C, Puyo A, Taira CA. Recent advances in obesity pharma-cotherapy. Curr Clin Pharmacol 2009; 4: 53-61.
2. Murray CJL, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223.
3. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. J Am Med Assoc 2007; 298: 2028-2037.
4. Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study. Int J Obes Relat Metab Disord 2003; 27: 1072-1080.
5. Hassan MK, Joshi AV, Madhavan SS, Amonkar MM. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003; 27: 1227-1232.
6. Counterweight Project Team. Evaluation of the Counterweight Programme for obesity management in primary care: a starting point for continuous improvement. Br J Gen Pract 2008; 58: 548-554.
7. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-The Evidence Report. Obes Res 1998; 6(Suppl 2): 51S-209S.
9. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000; 8: 270-278.
10. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
11. Look AHEAD Research GroupWing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575.
12. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
13. Astrup A. Drug management of obesity-efficacy versus safety. N Engl J Med 2010; 363: 288-290.
14. Field BC, Wren AM, Cooke D, Bloom SR. Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 2008; 68: 147-163.
15. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
16. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.
17. Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-86.
18. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
19. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-R856.
20. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
21. Williams DL, Baskin DG, Schwartz MW. Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety. Endocrinology 2009; 150: 1680-1687.
22. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25: 781-792.
23. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
24. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
25. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
26. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2011; 36: 843-854.
27. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010; 16(7 Suppl): S187-S194.
28. Isidro ML, Cordido F. Drug Treatment of obesity: Established and emerging therapies. Mini-Rev Med Chem 2009; 9: 664-673.
29. Davies MJ, Kela R, Khunti K. Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diab Obesity Metabol 2011; 13: 207-220.
30. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045.
31. Lean ME, James WP. Prescription of diabetic diets in the 1980s. Lancet 1986; 1: 723-725.
32. Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102-111.
33. Joelson S, Joelson IB, Wallander MA. Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf 1997; 6(Suppl 3): S31-S35.
34. Raisch DW, Troutman WG, Sather MR, Fudala PJ. Variability in the assessment of adverse events in a multicenter clinical trial. Clin Ther 2001; 23: 2011-2020.
35. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011; 7: 507-516.
36. Williams DL. Minireview: Finding the sweet spot: Peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009; 150: 2997-3001.
37. Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012; 97: 258-266.
38. Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diab Obes Metabol 2013, doi: 10.1111/dom.12108.
39. Seimon RV, Lange K, Little TJ, Brennan IM, Pilichiewicz AN, Feltrin KL et al. Pooled-data analysis identifies pyloric pressures and plasma cholecystokinin concentrations as major determinants of acute energy intake in healthy, lean men. Am J Clin Nutr 2010; 92: 61-68.
40. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135-148.
41. Vilsboll T, Krarup T, Madsbad S, Holst JJ. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 2001; 18: 144-149.
42. Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009; 43: 1433-1444.
43. Orskov C, Poulsen SS. M1ller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832-835.
44. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
45. Jelsing J, Vrang N, Hansen G, Ravn K, Tang-Christensen M, Knudsen LB. Liraglutide: Short lived effect on gastric emptying-long lasting effects on body-weight. Diab Obes Metabol 2012; 14: 531-538.
46. Hussain Z. Quigley EMM. Gastrointestinal issues in the assessment and management of the obese patient. Gastroenterol Hepatol 2007; 3: 559-569.